Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 247

1.

Rigging Innate Immunity against the Flu.

Krieg AM.

Mol Ther. 2017 Sep 6;25(9):1993-1994. doi: 10.1016/j.ymthe.2017.08.008. Epub 2017 Aug 23. No abstract available.

PMID:
28844477
2.

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga.

Aartsma-Rus A, Krieg AM.

Nucleic Acid Ther. 2017 Feb;27(1):1-3. doi: 10.1089/nat.2016.0657. Epub 2016 Dec 8. No abstract available.

3.

Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers.

Subramanian RR, Wysk MA, Ogilvie KM, Bhat A, Kuang B, Rockel TD, Weber M, Uhlmann E, Krieg AM.

Nucleic Acids Res. 2015 Oct 30;43(19):9123-32. doi: 10.1093/nar/gkv992. Epub 2015 Oct 7.

4.

Exon skipping therapy for Duchenne muscular dystrophy.

Kole R, Krieg AM.

Adv Drug Deliv Rev. 2015 Jun 29;87:104-7. doi: 10.1016/j.addr.2015.05.008. Epub 2015 May 14. Review.

PMID:
25980936
5.

CpG oligonucleotides protect against Venezuelan equine encephalitis virus infection in a route-dependent manner.

Rees DG, Phillpotts RJ, Griffin KF, Lukaszewski RA, Laws TR, Atkins HS, Krieg AM, Titball RW.

Int J Antimicrob Agents. 2013 Dec;42(6):587-8. doi: 10.1016/j.ijantimicag.2013.09.001. Epub 2013 Oct 1. No abstract available.

PMID:
24210643
6.

The ability of CpG oligonucleotides to protect mice against Francisella tularensis live vaccine strain but not fully virulent F. tularensis subspecies holarctica is reflected in cell-based assays.

Rees DG, Hartley MG, Green M, Lukaszewski RA, Griffin KF, Atkins HS, Lyons R, Krieg AM, Titball RW.

Microb Pathog. 2013 Oct;63:16-8. doi: 10.1016/j.micpath.2013.04.013. Epub 2013 May 22.

PMID:
23707360
7.

Targeting LDL Cholesterol With LNA.

Krieg AM.

Mol Ther Nucleic Acids. 2012 Jan 31;1:e6. doi: 10.1038/mtna.2011.8. No abstract available.

8.

Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery.

Nguyen DN, Mahon KP, Chikh G, Kim P, Chung H, Vicari AP, Love KT, Goldberg M, Chen S, Krieg AM, Chen J, Langer R, Anderson DG.

Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):E797-803. doi: 10.1073/pnas.1121423109. Epub 2012 Mar 15.

9.

Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.

La Rosa C, Longmate J, Lacey SF, Kaltcheva T, Sharan R, Marsano D, Kwon P, Drake J, Williams B, Denison S, Broyer S, Couture L, Nakamura R, Dadwal S, Kelsey MI, Krieg AM, Diamond DJ, Zaia JA.

J Infect Dis. 2012 Apr 15;205(8):1294-304. doi: 10.1093/infdis/jis107. Epub 2012 Mar 7. Erratum in: J Infect Dis. 2013 Sep;208(6):1038. Dadwal, Sanjeet [added].

10.

CpG still rocks! Update on an accidental drug.

Krieg AM.

Nucleic Acid Ther. 2012 Apr;22(2):77-89. doi: 10.1089/nat.2012.0340. Epub 2012 Feb 21. Review.

PMID:
22352814
11.

Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis.

Easton A, Haque A, Chu K, Patel N, Lukaszewski RA, Krieg AM, Titball RW, Bancroft GJ.

J Infect Dis. 2011 Aug 15;204(4):636-44. doi: 10.1093/infdis/jir301.

12.

Immunostimulatory potential of silencing RNAs can be mediated by a non-uridine-rich toll-like receptor 7 motif.

Jurk M, Chikh G, Schulte B, Kritzler A, Richardt-Pargmann D, Lampron C, Luu R, Krieg AM, Vicari AP, Vollmer J.

Nucleic Acid Ther. 2011 Jun;21(3):201-14. doi: 10.1089/nat.2011.0298.

PMID:
21749297
13.

Is RNAi dead?

Krieg AM.

Mol Ther. 2011 Jun;19(6):1001-2. doi: 10.1038/mt.2011.94. No abstract available.

14.

Subcutaneous, but not intratracheal administration of the TLR9 agonist, CpG DNA transiently reduces parainfluenza-3 virus shedding in newborn lambs.

Nichani AK, Dar MA, Mirakhur KK, Krieg AM, Booth JS, Townsend HG, Potter AA, Babiuk LA, Mutwiri GK.

Comp Immunol Microbiol Infect Dis. 2010 Dec;33(6):e111-7. doi: 10.1016/j.cimid.2010.06.003. Epub 2010 Jul 8.

PMID:
20619456
15.

Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environment.

Richardt-Pargmann D, Wechsler M, Krieg AM, Vollmer J, Jurk M.

Immunobiology. 2011 Jan-Feb;216(1-2):12-23. doi: 10.1016/j.imbio.2010.03.011. Epub 2010 Apr 9.

16.

AIMing 2 defend against intracellular pathogens.

Krieg AM.

Nat Immunol. 2010 May;11(5):367-9. doi: 10.1038/ni0510-367. No abstract available.

PMID:
20404848
17.

A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties.

Samulowitz U, Weber M, Weeratna R, Uhlmann E, Noll B, Krieg AM, Vollmer J.

Oligonucleotides. 2010 Apr;20(2):93-101. doi: 10.1089/oli.2009.0210.

PMID:
20384481
18.

AIMing 2 detect foreign DNA.

Krieg AM.

Sci Signal. 2009 Jun 30;2(77):pe39. doi: 10.1126/scisignal.277pe39.

PMID:
19567913
19.

CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.

Amemiya K, Meyers JL, Rogers TE, Fast RL, Bassett AD, Worsham PL, Powell BS, Norris SL, Krieg AM, Adamovicz JJ.

Vaccine. 2009 Apr 6;27(16):2220-9. doi: 10.1016/j.vaccine.2009.02.016. Epub 2009 Feb 13.

PMID:
19428836
20.

Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers.

Tarhini AA, Kirkwood JM, Krieg AM.

Expert Opin Drug Discov. 2009 May;4(5):587-603. doi: 10.1517/17460440902824784.

PMID:
23485088
21.

Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses.

Tluk S, Jurk M, Forsbach A, Weeratna R, Samulowitz U, Krieg AM, Bauer S, Vollmer J.

Int Immunol. 2009 May;21(5):607-19. doi: 10.1093/intimm/dxp030. Epub 2009 Mar 30.

22.

Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.

Vollmer J, Krieg AM.

Adv Drug Deliv Rev. 2009 Mar 28;61(3):195-204. doi: 10.1016/j.addr.2008.12.008. Epub 2009 Jan 13. Review.

PMID:
19211030
23.

Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy.

Kline JN, Krieg AM.

Drug News Perspect. 2008 Oct;21(8):434-9. doi: 10.1358/dnp.2008.21.8.1272133. Review.

PMID:
19034349
24.

NK cells activated in vivo by bacterial DNA control the intracellular growth of Francisella tularensis LVS.

Elkins KL, Colombini SM, Krieg AM, De Pascalis R.

Microbes Infect. 2009 Jan;11(1):49-56. doi: 10.1016/j.micinf.2008.10.005. Epub 2008 Oct 22.

PMID:
18992838
25.

Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse.

Vicari AP, Luu R, Zhang N, Patel S, Makinen SR, Hanson DC, Weeratna RD, Krieg AM.

Cancer Immunol Immunother. 2009 Apr;58(4):615-28. doi: 10.1007/s00262-008-0586-2. Epub 2008 Sep 19.

PMID:
18802696
26.

CD14+ cells are required for IL-12 response in bovine blood mononuclear cells activated with Toll-like receptor (TLR) 7 and TLR8 ligands.

Buza J, Benjamin P, Zhu J, Wilson HL, Lipford G, Krieg AM, Babiuk LA, Mutwiri GK.

Vet Immunol Immunopathol. 2008 Dec 15;126(3-4):273-82. doi: 10.1016/j.vetimm.2008.08.001. Epub 2008 Aug 20.

PMID:
18789542
27.

Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.

Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G, Al-Adhami M, Readett D, Krieg AM, Leichman CG.

J Clin Oncol. 2008 Aug 20;26(24):3979-86. doi: 10.1200/JCO.2007.12.5807.

PMID:
18711188
28.

A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity.

Fukuiwa T, Sekine S, Kobayashi R, Suzuki H, Kataoka K, Gilbert RS, Kurono Y, Boyaka PN, Krieg AM, McGhee JR, Fujihashi K.

Vaccine. 2008 Sep 2;26(37):4849-59. doi: 10.1016/j.vaccine.2008.06.091. Epub 2008 Jul 14.

29.

TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection.

Taylor PA, Ehrhardt MJ, Lees CJ, Panoskaltsis-Mortari A, Krieg AM, Sharpe AH, Murphy WJ, Serody JS, Hemmi H, Akira S, Levy RB, Blazar BR.

Blood. 2008 Oct 15;112(8):3508-16. doi: 10.1182/blood-2007-09-113670. Epub 2008 Jul 9.

30.

Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers.

Cooper CL, Ahluwalia NK, Efler SM, Vollmer J, Krieg AM, Davis HL.

J Immune Based Ther Vaccines. 2008 Jun 9;6:3. doi: 10.1186/1476-8518-6-3.

31.

Toll-like receptor 9 regulates the lung macrophage phenotype and host immunity in murine pneumonia caused by Legionella pneumophila.

Bhan U, Trujillo G, Lyn-Kew K, Newstead MW, Zeng X, Hogaboam CM, Krieg AM, Standiford TJ.

Infect Immun. 2008 Jul;76(7):2895-904. doi: 10.1128/IAI.01489-07. Epub 2008 Apr 21.

32.

Attenuated cytokine responses in porcine lymph node cells stimulated with CpG DNA are associated with low frequency of IFNalpha-producing cells and TLR9 mRNA expression.

Dar A, Nichani AK, Benjamin P, Lai K, Soita H, Krieg AM, Potter A, Babiuk LA, Mutwiri GK.

Vet Immunol Immunopathol. 2008 Jun 15;123(3-4):324-36. doi: 10.1016/j.vetimm.2008.02.007. Epub 2008 Feb 17.

PMID:
18367252
33.

Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands.

Martinson JA, Roman-Gonzalez A, Tenorio AR, Montoya CJ, Gichinga CN, Rugeles MT, Tomai M, Krieg AM, Ghanekar S, Baum LL, Landay AL.

Cell Immunol. 2007 Nov-Dec;250(1-2):75-84. doi: 10.1016/j.cellimm.2008.01.007. Epub 2008 Mar 10.

34.

Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses.

Forsbach A, Nemorin JG, Montino C, Müller C, Samulowitz U, Vicari AP, Jurk M, Mutwiri GK, Krieg AM, Lipford GB, Vollmer J.

J Immunol. 2008 Mar 15;180(6):3729-38.

35.

Immunology. The toll of cathepsin K deficiency.

Krieg AM, Lipford GB.

Science. 2008 Feb 1;319(5863):576-7. doi: 10.1126/science.1154207. No abstract available.

PMID:
18239112
36.

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer.

Krieg AM.

Oncogene. 2008 Jan 7;27(2):161-7. doi: 10.1038/sj.onc.1210911. Review.

PMID:
18176597
37.

Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques.

Stewart VA, McGrath S, Krieg AM, Larson NS, Angov E, Smith CL, Brewer TG, Heppner DG Jr.

Clin Vaccine Immunol. 2008 Feb;15(2):221-6. Epub 2007 Dec 12.

38.

The toll of too much TLR7.

Krieg AM.

Immunity. 2007 Nov;27(5):695-7. Review.

39.

The CpG motif: implications for clinical immunology.

Krieg AM.

BioDrugs. 1998 Nov;10(5):341-6.

PMID:
18020606
40.

Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity.

Krieg AM, Vollmer J.

Immunol Rev. 2007 Dec;220:251-69. Review.

PMID:
17979852
41.

Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.

Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, Hainsworth J, Sparano JA, Tsai DE, Horning S, Krieg AM, Weiner GJ.

Clin Cancer Res. 2007 Oct 15;13(20):6168-74.

42.

TLR9 is required for protective innate immunity in Gram-negative bacterial pneumonia: role of dendritic cells.

Bhan U, Lukacs NW, Osterholzer JJ, Newstead MW, Zeng X, Moore TA, McMillan TR, Krieg AM, Akira S, Standiford TJ.

J Immunol. 2007 Sep 15;179(6):3937-46.

43.

Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist.

Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Laframboise C, Leese P, Krieg AM, Efler SM, Davis HL.

Antivir Ther. 2007;12(5):741-51.

PMID:
17713157
44.

Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself.

Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, Krieg AM, Levy R.

J Immunol. 2007 Aug 15;179(4):2493-500.

45.

Antiinfective applications of toll-like receptor 9 agonists.

Krieg AM.

Proc Am Thorac Soc. 2007 Jul;4(3):289-94. Review.

47.

Development of TLR9 agonists for cancer therapy.

Krieg AM.

J Clin Invest. 2007 May;117(5):1184-94. Review.

48.

TLR9 and DNA 'feel' RAGE.

Krieg AM.

Nat Immunol. 2007 May;8(5):475-7. No abstract available.

PMID:
17440455
49.

Toll-free vaccines?

Krieg AM.

Nat Biotechnol. 2007 Mar;25(3):303-5. No abstract available. Erratum in: Nat Biotechnol. 2007 Jun;25(6):687.

PMID:
17344883
50.

Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals.

Martinson JA, Tenorio AR, Montoya CJ, Al-Harthi L, Gichinga CN, Krieg AM, Baum LL, Landay AL.

Immunology. 2007 Apr;120(4):526-35.

Supplemental Content

Loading ...
Support Center